<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02824835</url>
  </required_header>
  <id_info>
    <org_study_id>IDO123</org_study_id>
    <nct_id>NCT02824835</nct_id>
  </id_info>
  <brief_title>Strigolactones and Dysplastic Colonic Lesions or Cancer</brief_title>
  <official_title>The Effect of the Plant Hormones Strigolactones on Cultures of Dysplastic Colonic Lesions and Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of the plant hormones strigolactones,
      on cell cultures of colonic polyps and colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Strigolactones have been shown to anti-proliferative and pro-apoptotic effects in cell
      cultures of breast and prostate origin, partially by down-regulation of cyclin B1 and
      induction of cell cycle arrest. In this study the investigators intend to take biopsies from
      benign colonic polyps and cancer tissue, culture intestinal explants and generate
      immortalized primary cells as a platform to assess the effect of this plant hormone on cell
      viability, cell mobility, apoptosis and cytoskeleton modifications.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of cells with reduced viability after dose-dependent exposure</measure>
    <time_frame>24 hours of exposure to strigolactone</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>percentage of cells in G2/M arrest after dose-dependent exposure</measure>
    <time_frame>24 hours of exposure to strigolactone</time_frame>
    <description>analysis of cell cycle</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Colonic Neoplasms</condition>
  <condition>Colonic Polyps</condition>
  <arm_group>
    <arm_group_label>adenoma group</arm_group_label>
    <description>Patients with adenoma. Biopsies are taken before endoscopic resection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cancer group</arm_group_label>
    <description>Patients with colorectal cancer. Biopsies are taken before surgical resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy during colonoscopy</intervention_name>
    <description>sampling the lesion with forcept biopter</description>
    <arm_group_label>adenoma group</arm_group_label>
    <arm_group_label>cancer group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing colonoscopy who have positive findings (polyps, cancer) during the
        procedure
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with positive findings during colonoscopy

        Exclusion Criteria:

          -  Patients below 18 years old

          -  Patients who cannot sign a consent form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ido Laish, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meir Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ido Laish, MD</last_name>
    <phone>+ 972-9-7473261</phone>
    <email>ido.lish@clalit.org.il</email>
  </overall_contact>
  <reference>
    <citation>Mayzlish-Gati E, Laufer D, Grivas CF, Shaknof J, Sananes A, Bier A, Ben-Harosh S, Belausov E, Johnson MD, Artuso E, Levi O, Genin O, Prandi C, Khalaila I, Pines M, Yarden RI, Kapulnik Y, Koltai H. Strigolactone analogs act as new anti-cancer agents in inhibition of breast cancer in xenograft model. Cancer Biol Ther. 2015;16(11):1682-8. doi: 10.1080/15384047.2015.1070982. Epub 2015 Jul 20.</citation>
    <PMID>26192476</PMID>
  </reference>
  <reference>
    <citation>Pollock CB, Koltai H, Kapulnik Y, Prandi C, Yarden RI. Strigolactones: a novel class of phytohormones that inhibit the growth and survival of breast cancer cells and breast cancer stem-like enriched mammosphere cells. Breast Cancer Res Treat. 2012 Aug;134(3):1041-55. doi: 10.1007/s10549-012-1992-x. Epub 2012 Mar 29.</citation>
    <PMID>22476848</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2016</study_first_submitted>
  <study_first_submitted_qc>July 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>July 2, 2016</last_update_submitted>
  <last_update_submitted_qc>July 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Meir Medical Center</investigator_affiliation>
    <investigator_full_name>ido laish</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Polyps</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

